GB201816639D0 - GLP-1 Receptor Antagonist - Google Patents

GLP-1 Receptor Antagonist

Info

Publication number
GB201816639D0
GB201816639D0 GBGB1816639.7A GB201816639A GB201816639D0 GB 201816639 D0 GB201816639 D0 GB 201816639D0 GB 201816639 A GB201816639 A GB 201816639A GB 201816639 D0 GB201816639 D0 GB 201816639D0
Authority
GB
United Kingdom
Prior art keywords
glp
receptor antagonist
antagonist
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1816639.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Priority to GBGB1816639.7A priority Critical patent/GB201816639D0/en
Publication of GB201816639D0 publication Critical patent/GB201816639D0/en
Priority to CA3115448A priority patent/CA3115448A1/en
Priority to PCT/GB2019/052915 priority patent/WO2020074927A2/en
Priority to CN201980080295.9A priority patent/CN113166206A/zh
Priority to JP2021520179A priority patent/JP7492507B2/ja
Priority to AU2019358324A priority patent/AU2019358324B2/en
Priority to US17/284,351 priority patent/US12441777B2/en
Priority to EP19790753.8A priority patent/EP3863661A2/en
Priority to US19/251,101 priority patent/US20250368709A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB1816639.7A 2018-10-12 2018-10-12 GLP-1 Receptor Antagonist Ceased GB201816639D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1816639.7A GB201816639D0 (en) 2018-10-12 2018-10-12 GLP-1 Receptor Antagonist
CA3115448A CA3115448A1 (en) 2018-10-12 2019-10-14 Glp-1 receptor antagonists
PCT/GB2019/052915 WO2020074927A2 (en) 2018-10-12 2019-10-14 Glp-1 receptor antagonists
CN201980080295.9A CN113166206A (zh) 2018-10-12 2019-10-14 Glp-1受体拮抗剂
JP2021520179A JP7492507B2 (ja) 2018-10-12 2019-10-14 Ｇｌｐ－１受容体アンタゴニスト
AU2019358324A AU2019358324B2 (en) 2018-10-12 2019-10-14 GLP-1 receptor antagonists
US17/284,351 US12441777B2 (en) 2018-10-12 2019-10-14 GLP-1 receptor antagonists
EP19790753.8A EP3863661A2 (en) 2018-10-12 2019-10-14 Glp-1 receptor antagonists
US19/251,101 US20250368709A1 (en) 2018-10-12 2025-06-26 Glp-1 receptor antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1816639.7A GB201816639D0 (en) 2018-10-12 2018-10-12 GLP-1 Receptor Antagonist

Publications (1)

Publication Number Publication Date
GB201816639D0 true GB201816639D0 (en) 2018-11-28

Family

ID=64397527

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1816639.7A Ceased GB201816639D0 (en) 2018-10-12 2018-10-12 GLP-1 Receptor Antagonist

Country Status (8)

Country Link
US (2) US12441777B2 (https=)
EP (1) EP3863661A2 (https=)
JP (1) JP7492507B2 (https=)
CN (1) CN113166206A (https=)
AU (1) AU2019358324B2 (https=)
CA (1) CA3115448A1 (https=)
GB (1) GB201816639D0 (https=)
WO (1) WO2020074927A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202011604D0 (en) * 2020-07-27 2020-09-09 Heptares Therapeutics Ltd GLP-1 receptor antagonists
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
CN100540565C (zh) 2005-01-14 2009-09-16 无锡宏创医药科技有限公司 修饰的Exendins及其应用
WO2007139941A2 (en) 2006-05-26 2007-12-06 Amylin Pharmaceuticals, Inc. Composition and methods for treatment of congestive heart failure
WO2010032509A1 (ja) * 2008-09-20 2010-03-25 国立大学法人京都大学 膵島イメージング用分子プローブ前駆体及びその使用
WO2010120476A2 (en) 2009-04-01 2010-10-21 Amylin Pharmaceuticals, Inc. N-terminus conformationally constrained glp-1 receptor agonist compounds
CN101870728A (zh) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
WO2011027584A1 (ja) * 2009-09-04 2011-03-10 国立大学法人京都大学 膵島イメージング用分子プローブ及びその使用
US9278146B2 (en) * 2010-10-08 2016-03-08 Kyoto University Peptide derivative and use of the same
CN102532301B (zh) * 2010-12-31 2014-09-03 上海医药工业研究院 一类新型的Exendin-4类似物及其制备方法
GB201315335D0 (en) * 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
LT3297653T (lt) * 2015-05-22 2022-01-10 The Board Of Trustees Of The Leland Stanford Junior University Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais

Also Published As

Publication number Publication date
AU2019358324B2 (en) 2025-05-22
AU2019358324A1 (en) 2021-04-22
CA3115448A1 (en) 2020-04-16
JP7492507B2 (ja) 2024-05-29
US12441777B2 (en) 2025-10-14
CN113166206A (zh) 2021-07-23
US20250368709A1 (en) 2025-12-04
US20210355186A1 (en) 2021-11-18
WO2020074927A2 (en) 2020-04-16
JP2022504798A (ja) 2022-01-13
WO2020074927A3 (en) 2020-12-17
EP3863661A2 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
HUE070634T2 (hu) GLP-1 receptor agonista
IL287166A (en) A pyrazolopyridine derivative with an agonistic effect on the glp-1 receptor
ZA201804997B (en) Triple glucagon/glp-1/gip receptor agonist
GB201911187D0 (en) Receptor
PT3814341T (pt) Inibidores de recetor erbb
GB201905552D0 (en) Antagonists
IL287617A (en) Hmgb1 antagonist
IL258892B (en) Calcitonin gene-related peptide receptor antagonists
GB2551945B (en) Novel GLP-1 receptor agonist peptides
IL279960A (en) P2X3 receptor antagonists
ZA201800452B (en) Cgrp receptor antagonists
GB201519195D0 (en) CGRP Receptor Antagonists
GB201815629D0 (en) Antagonists
GB201801831D0 (en) Chimeric receptor
GB201816639D0 (en) GLP-1 Receptor Antagonist
GB201519194D0 (en) CGRP receptor antagonists
GB202011604D0 (en) GLP-1 receptor antagonists
EP3388423A4 (en) ANTAGONIST OF THE RECEIVER NK1
SG11202106401UA (en) Estrogen receptor antagonist
GB201816650D0 (en) GLP-1 Receptor antagonists
GB201910515D0 (en) GLP-1 Receptor antagonists
HK40040824A (en) Glucagon receptor antagonists
GB201910526D0 (en) Antagonist
GB201909500D0 (en) Antagonist
SG11202105784WA (en) Antagonists

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)